copper-64 labeled granzyme b
Recombinant proteinexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 25, 2023 (NCT05888532)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06522932 | Phase 1 | Oct 30, 2024 | University of California, San Francisco, V Foundation |
| NCT05888532 | Phase 1/Phase 2 (Phase 2) | May 25, 2023 | National Cancer Institute (NCI), United States Army, University of California, San Francisco |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 2 | 2023 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
| United States Army | Government | 1 | 0 | 1 | 2023 |
| V Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1